Unilabs acquires CMDI, enters radiology segment in Spain
European diagnostic services provider Unilabs has acquired CMDI, an independent imaging diagnostics company in Spain. “This deal significantly grows Unilabs’ business in Spain, and marks our entry into the important radiology segment there,” said Jos Lamers, Unilabs Executive Chairman. CMDI is an effective operation with close to 50 sites, more than 100 employees, and a medical team of 30-plus radiologists. The company has a strong presence in Spain, particularly in Andalusia. Unilabs intends to build CMDI into a leading player in the Spanish radiology market by expanding the service portfolio, growing the teleradiology business, and continuing the successful strategy of selective acquisitions.
Trikafta: FDA approves new breakthrough therapy for cystic fibrosis
The U.S. Food and Drug Administration (FDA) approved Trikafta (elexacaftor/ivacaftor/tezacaftor), the first triple combination therapy available to treat patients with the most common cystic fibrosis (CF) mutation. Trikafta is approved for patients 12 years and older with CF who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which is estimated to represent 90% of the CF population. Trikafta is a combination of three drugs that target the defective CFTR protein. It helps the protein made by the CFTR gene mutation function more effectively. Currently available therapies that target the defective protein are treatment options for some patients with cystic fibrosis, but many patients have mutations that are ineligible for treatment. More information on the FDA website.
Olympus takes over Versapoint Electrosurgery tech
Olympus Corporation announced today that it entered an agreement with Ethicon, Inc., in which Olympus will take over all new commercial activities related to the Versapoint™ Electrosurgery system from Ethicon. With this agreement, Olympus will acquire new channels in its Gynecology Business toward its goal of bringing patients and customers more minimally invasive technology and product options. The system is used for the treatment of various intrauterine pathologies such as myomas, polyps, intrauterine adhesions and uterine septa. Details on the agreement on the Olympus Europe website.